Abstract:Heart failure (HF) with preserved ejection fraction (HFpEF) is the most common cause of pulmonary hypertension (PH) worldwide and is strongly associated with adverse clinical outcomes. The American Heart Association recently highlighted a call to action regarding the distinct lack of evidence-based treatments for PH due to poorly understood pathophysiology of PH attributable to HFpEF (PH-HFpEF). Prior studies have described cardiophysiological mechanisms to explain the development of isolated postcapillary PH (ipc-PH); however, the consequent increase in pulmonary vascular (PV) resistance (PVR) may lead to the less understood and more fatal combined pre- and postcapillary PH (cpc-PH). Metabolic disease and inflammatory dysregulation have been suggested to predispose PH, yet the molecular mechanisms are unknown. Although PH-HFpEF has been studied to partly share vasoactive neurohormonal mediators with primary pulmonary arterial hypertension (PAH), clinical trials that have targeted these pathways have been unsuccessful. The increased mortality of patients with PH-HFpEF necessitates further study into viable mechanistic targets involved in disease progression. We aim to summarize the current pathophysiological and clinical understanding of PH-HFpEF, highlight the role of known molecular mechanisms in the progression of PV disease, and introduce a novel concept that lipid metabolism may be attenuating and propagating PH-HFpEF.NEW & NOTEWORTHY Our review addresses pulmonary hypertension (PH) attributable to heart failure (HF) with preserved ejection fraction (HFpEF; PH-HFpEF). Current knowledge gaps in PH-HFpEF pathophysiology have led to a lack of therapeutic targets. Thus, we address identified knowledge gaps in a comprehensive review, focusing on current clinical epidemiology, known pathophysiology, and previously studied molecular mechanisms. We also introduce a comprehensive review of polyunsaturated fatty acid (PUFA) lipid inflammatory mediators in PH-HFpEF.

Exploring the pathogenesis of pulmonary vascular disease

Epigenetic Regulation of Pulmonary Arterial Hypertension

Epigenetic Modulation in the Initiation and Progression of Pulmonary Hypertension.

Epigenetic Regulation and Its Therapeutic Potential in Pulmonary Hypertension

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives

Mechanisms of lung endothelial cell injury and survival in pulmonary arterial hypertension

A peripheral system disease-Pulmonary hypertension

Molecular genetic framework underlying pulmonary arterial hypertension

Emerging Epigenetic Targets and Their Molecular Impact on Vascular Remodeling in Pulmonary Hypertension

Clinical features of chronic obstructive pulmonary disease with pulmonary hypertension

Focus on Early Events: Pathogenesis of Pulmonary Arterial Hypertension Development

Pulmonary arterial hypertension: Navigating the pathways of progress in diagnosis, treatment, and patient care

New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis

Novel insights into the pathobiology of pulmonary hypertension in heart failure with preserved ejection fraction

Pathogenesis of pulmonary hypertension caused by left heart disease

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

Updated perspective of EPAS1 and the role in pulmonary hypertension

Pathology and pathobiology of pulmonary hypertension: current insights and future directions

Unraveling the epigenetic landscape of pulmonary arterial hypertension: implications for personalized medicine development

Pulmonary Hypertension: A Contemporary Review

New progress in diagnosis and treatment of pulmonary arterial hypertension